Cannabinoids as therapeutic agents in cardiovascular disease: A tale of passions and illusions

British Journal of Pharmacology

Volumn 151, Issue 4, 2007, Pages 427-440

  Mendizabal V E ^a   Adler Graschinsky, E ^a  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

Author keywords

Cannabis; Endocannabinoids; Hypertension; Medical use; Rimonabant; Shock

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANTIHYPERTENSIVE AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; METHANANDAMIDE; MORPHINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; NITRIC OXIDE; O 1918; OMDM 2; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; ATHEROSCLEROSIS; BRADYCARDIA; BRAIN ISCHEMIA; CANADA; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEGRADATION; DISEASE COURSE; DRUG APPROVAL; DRUG INDUSTRY; DRUG SYNTHESIS; ENDOTHELIAL DYSFUNCTION; ENDOTOXEMIA; EPILEPSY; ESSENTIAL HYPERTENSION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOTENSION; IMMUNOMODULATION; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER CIRRHOSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBID OBESITY; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; STANDARDIZATION; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TOBACCO DEPENDENCE; UNITED STATES; VASODILATATION; WEIGHT REDUCTION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; CANNABINOIDS; CARDIOVASCULAR DISEASES; ENDOCANNABINOIDS; EXERCISE; HEART RATE; HUMANS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 34250213868     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707261     Document Type: Review

References (136)

1. Adams MD, Chait LD, Earnhardt JT (1976). Tolerance to the cardiovascular effects of delta9-tetrahydrocannabinol in the rat. Br J Pharmacol 56: 43-48.
2. Archer RA (1974). The cannabinoids: therapeutic potentials. Annu Rep Med Chem 9: 253-259.
3. Bátkai S, Jarai Z, Wagner JA, Goparaju SK, Varga K, Liu J et al. (2001). Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7: 827-832.
4. Bátkai S, Pacher P, Jarai Z, Wagner JA, Kunos G (2004a). Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol 287: H595-H600.
5. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J et al. (2004b). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996-2002.
6. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM et al. (2005). Evidence for novel cannabinoid receptors. Pharmacol Ther 106: 133-145.
7. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high affinity anandamide transport, as revealed by selective inhibition. Science 277: 1094-1097.
8. Benowitz NL, Jones RT (1975). Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 18: 287-297.
9. Benowitz NL, Jones RT (1981). Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21: 214S-223S.
10. Benowitz NL, Rosenberg J, Rogers W, Bachman J, Jones RT (1979). Cardiovascular effects of intravenous delta-9-tetrahydrocanabinol: autonomic nervous mechanisms. Clin Pharmacol Ther 25: 440-446.
11. Bilfinger TV, Salzet M, Fimiani C, Deutsch DG, Tramu G, Stefano GB (1998). Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol 64 (Suppl 1): S15-S22.
12. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V (1997). Biosynthesis, release and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323.
13. Bolli R (2000). The late phase of preconditioning. Circ Res 87: 972-983.
14. 1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41: 657-664.
15. 2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 274: 20397-20405.
16. 2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82: 1131-1149.
17. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141-149.
18. Cannon CP (2005). The endocannabinoid system: a new approach to control cardiovascular disease. Clin Cornerstone 7: 17-26.
19. Chataigneau T, Feletou M, Thollon C, Villeneuve N, Vilaine JP, Duhault J et al. (1998). Cannabinoid CB1 receptor and endothelium-dependent hyperpolarization in guinea-pig carotid, rat mesenteric and porcine coronary arteries. Br J Pharmacol 123: 968-974.
20. Chaytor AT, Martin PEM, Evans WH, Randall MD, Griffith TM (1999). The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520: 539-550.
21. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M et al. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431.
22. Cravatt BF, Lichtman AH (2003). Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7: 469-475.
23. Cravatt BF, Lichtman AH (2004). The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61: 149-160.
24. CRESCENDO (Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes). Available at http://www.clinicaltrials.gov/ct/gui/show/ NCT00263042?order=2,Accessed November 16, 2006.
25. Deutsch DG, Chin SA (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46: 791-796.
26. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK et al. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100: 1538-1546.
27. Devane WA, Dysarz FA, Johnson LS, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
28. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
29. Dewey WL (1986). Cannabinoid Pharmacology. Pharmacol Rev 38: 151-178.
30. Marzo V, De Petrocellis L (2006). Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 57: 553-574.
31. Marzo V, De Petrocellis L, Sepe N, Buono A (1996). Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316: 977-984.
32. Dietrich A, McDaniel WF (2004). Endocannabinoids and exercise. Br J Sports Med 38: 536-541.
33. Dishman RK, Berthoud HR, Booth FW, Cotman CW, Edgerton VR, Fleshner MR et al. (2006). Neurobiology of exercise. Obesity (Silver Spring) 14: 345-356.
34. Ellis EF, Moore SF, Willoughby KA (1995). Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol 269: H1859-H1864.
35. Ford WR, Honan SA, White R, Hiley CR (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilator responses in rat isolated hearts. Br J Pharmacol 135: 1191-1198.
36. Fredericks AB, Benowitz NL, Savanapridi CY (1981). The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. J Pharmacol Exp Ther 216: 247-253.
37. Fulton D, Quilley J (1998). Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat. J Pharmacol Exp Ther 286: 1146-1151.
38. 1 spinal receptors in urethane-anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 368: 270-276.
39. García MC, Adler-Graschinsky E, Celuch SM (2006). Role of CGRP and GABA in the hypotensive effect of intrathecally administered anandamide to anesthetized rats. Eur J Pharmacol 532: 88-98.
40. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS (2005). Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 146: 315-323.
41. 2+ channel current. Am J Physiol 276: H2085-H2093.
42. Gelfand EV, Cannon CP (2006). Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 47: 1919-1926.
43. Godlewski G, Malinowska B, Schlicker E. (2004). Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br J Pharmacol 142: 701-708.
44. Grainger J, Boachie-Ansah G (2001). Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134: 1003-1012.
45. Hájos N, Ledent C, Freund TF (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106: 1-4.
46. Hardman HF, Domino EF, Seevers MH (1971). General pharmacological actions of some synthetic tetrahydrocannabinol derivatives. Pharmacol Rev 23: 295-315.
47. Harris D, McCulloch AI, Kendall DA, Randall MD (2002). Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol 539: 893-902.
48. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci 11: 563-583.
49. Hiley CR, Ford WR (2004). Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc 79: 187-205.
50. Hillard CJ (2000). Endocannabinoids and vascular function. J Pharmacol Exp Ther 294: 27-32.
51. Högestatt ED, Zygmunt PM (2002). Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 66: 343-351.
52. House of Lords (1998). Science and Technology - Ninth Report. Science and Technology Committee Publications.
53. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
54. 1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118: 2023-2028.
55. 2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
56. Jones RT (2002). Cardiovascular system effects of marijuana. J Clin Pharmacol 42: 58S-63S.
57. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C (2002). Endocannabinoids are implicated in the infarct size reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55: 619-625.
58. Kalant H (2001). Medicinal use of cannabis: history and current status. Pain Res Manag 6: 80-91.
59. Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U et al. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14: 3389-3396.
60. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
61. Kosersky DS (1978). Antihypertensive effects of delta9-tetrahydro- cannabinol. Arch Int Pharmacodyn Ther 233: 76-81.
62. Kunos G., Jarai Z., Batkai S, Goparaju SK, Ishac EJ, Liu J et al. (2000). Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 108: 159-168.
63. Lagneux C, Lamontagne D (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 132: 793-796.
64. Lake KD, Compton DR, Varga K, Martin BR, Kunos G (1997). Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther 281: 1030-1037.
65. 2 cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1440: 266-274.
66. Lamontagne D, Lepicier P, Lagneux C, Bouchard JF (2006). The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia. Arch Mal Coeur Vaiss 99: 242-246.
67. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
68. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D (2003). Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 139: 805-815.
69. J, Kaminski NE, Wang DH (2003). Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor. Hypertension 41: 757-762.
70. Libby P, Theroux P (2005). Pathophysiology of coronary artery disease. Circulation 111: 3481-3488.
71. 1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346: 835-840.
72. Mackie K (2006). Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101-122.
73. Mackie K, Stella N (2006). Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8: E298-E306.
74. + channel TASK-1. EMBO J 20: 47-54.
75. Marai S (2001). Embers. Penguin: Melbourne.
76. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
77. Mechoulam R, Gaoni Y (1967). The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 12: 1109-1111.
78. Mendizábal VE, Orliac ML, Adler-Graschinsky E (2001). Long-term inhibition of nitric oxide synthase potentiates effects of anandamide in the rat mesenteric bed. Eur J Pharmacol 427: 251-262.
79. Mukhopadhyay S, Chapnick BM, Howlett AC (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 282: H2046-H2054.
80. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
81. Niederhoffer N, Szabo B (1999). Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 126: 457-466.
82. Niederhoffer N, Szabo B (2000). Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther 294: 707-713.
83. 2, regulates bone mass. Proc Natl Acad Sci USA 103: 696-701.
84. Offertáler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
85. Orliac ML, Peroni R, Celuch SM, Adler-Graschinsky E (2003). Potentiation of anandamide effects in mesenteric beds isolated from endotoxemic rats. J Pharmacol Exp Ther 304: 179-184.
86. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S et al. (2005). Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115: 1298-1305.
87. Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. (2006). The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes (London) 30: S33-S38.
88. O'Sullivan SE, Kendall DA, Randall MD (2004). Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl- dopamine (NADA). Br J Pharmacol 141: 803-812.
89. 1 receptor knock-out mice. J Physiol 558: 647-657.
90. Pacher P, Bátkai S, Kunos G (2005a). Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48: 1130-1138.
91. Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
92. Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Liu J, Harvey-White J et al. (2005b). Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 289: H533-H541.
93. Padley JR, Li Q, Pilowsky PM, Goodchild AK (2003). Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats. Br J Pharmacol 140: 384-394.
94. Parrillo JE (1993). Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477.
95. Peroni RN, Orliac ML, Abramoff T, Ribeiro ML, Franchi AM, Adler-Graschinsky E (2007). Participation of CGRP and prostanoids in the sex-linked differences of anandamide effects in mesenteric beds isolated from Sprague-Dawley rats. Eur J Pharmacol 557: 49-57.
96. Peroni RN, Orliac ML, Becu-Villalobos D, Huidobro-Toro JP, Adler-Graschinsky E, Celuch SM (2004). Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. Eur J Pharmacol 493: 151-160.
97. Pfitzer T, Niederhoffer N, Szabo B (2005). Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system. Naunyn-Schmiedeberg's Arch Pharmacol 371: 9-17.
98. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775.
99. Plane F, Holland M, Waldron GL, Garland CJ, Boyle JP (1997). Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br J Pharmacol 121: 1509-1512.
100. 1 receptor activation in the rat arterial mesenteric bed. J Physiol 568: 539-551.
101. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB (1998). N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol 274: H375-H381.
102. Ralevic V, Kendall DA (2002). Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur J Pharmacol 444: 171-181.
103. Randall MD, Alexander SP, Bennett T, Boyd EA, Fry JR, Gardiner SM et al. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 229: 114-120.
104. Randall MD, Harris D, Kendall DA, Ralevic V (2002). Cardiovascular effects of cannabinoids. Pharmacol Ther 95: 191-202.
105. Randall MD, Kendall DA, O'Sullivan S (2004). The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20-26.
106. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-R353.
107. Ros J, Claria J, To-Figueras J, Planaguma A, Cejudo-Martín P, Fernández-Varo G et al. (2002). Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122: 85-93.
108. Ross RA, Brockie HC, Pertwee RG (2000). Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 401: 121-130.
109. Schmid PC, Kuwae T, Krebsbach RJ, Schmid HH (1997). Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. Chem Phys Lipids 87: 103-110.
110. 2 receptor activation and nitric oxide production. Mol Cell Biochem 283: 75-83.
111. Siqueira SW, Lapa AP, Ribeiro do Valle J (1979). The triple effect induced by delta 9-tetrahydrocannabinol on the rat blood pressure. Eur J Pharmacol 58: 351-357.
112. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A (2003). Exercise activates the endocannabinoid system. Neuroreport 14: 2209-2211.
113. Steffens S, Mach F (2006). Cannabinoid receptors in atherosclerosis. Curr Opin Lipidol 17: 519-526.
114. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C et al. (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786.
115. STRADIVARIUS (Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant - the Intravascular Ultrasound Study). Available at http://www.clinicaltrials.gov/ct/gui/show/NCT00124332?order=1,Accessed November 16 2006.
116. Terenius L (2000). From opiate pharmacology to opioid peptide physiology. Ups J Med Sci 105: 1-15.
117. Tonstad S (2006). Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr Metab Cardiovasc Dis 16: 156-162.
118. Underdown NJ, Hiley CR, Ford WR (2005). Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 146: 809-816.
119. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397.
120. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278: 279-283.
121. Varga K, Wagner JA, Bridgen DT, Kunos G (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044.
122. Vidrio H, Sanchez-Salvatori MA, Medina M (1996). Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 28: 332-336.
123. Vollmer RR, Cavero I, Ertel RJ, Solomon TA, Buckley JP (1974). Role of the central autonomic nervous system in the hypotension and bradycardia induced by (-)-delta 9-trans-tetrahydrocannabinol. J Pharm Pharmacol 26: 186-192.
124. 1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol 47: 650-655.
125. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK et al. (2001b). Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38: 2048-2054.
126. Wagner JA, Hu K, Karcher J, Bauersachs J, Schafer A, Laser M et al. (2003). CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 138: 1251-1258.
127. Wagner JA, Jarai Z, Batkai S, Kunos G (2001a). Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423: 203-210.
128. 1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518-521.
129. Wagner JA, Varga K, Jarai Z, Kunos G (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33: 429-434.
130. Wagner JA, Varga K, Kunos G (1998). Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 76: 824-836.
131. Walter L, Stella N (2004). Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785.
132. 1-mediated depressor effects during high-salt intake: role of anandamide. Hypertension 46: 986-991.
133. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M et al. (2001). Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294: 73-82.
134. White R, Hiley CR (1997). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol 122: 1573-1584.
135. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB et al. (2007). Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 354: 427-433.
136. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.